CHEMICAL AND PHYSICAL PROPERTIES
| Color/Form | White to yellow powder |
|---|---|
| Stability/Shelf Life | Chemical stability: Material is stable under normal conditions. |
| Decomposition | Hazardous decomposition products: Irritating and/or toxic fumes and gases may be emitted upon the products decomposition. |
| Other Experimental Properties | Solvent is clear, colorless; reconstituted solution is yellow |
COMPUTED DESCRIPTORS
| Molecular Weight | 3283.6 g/mol |
|---|---|
| XLogP3 | -14.6 |
| Hydrogen Bond Donor Count | 49 |
| Hydrogen Bond Acceptor Count | 50 |
| Rotatable Bond Count | 109 |
| Exact Mass | 3282.6502800 g/mol |
| Monoisotopic Mass | 3281.6469252 g/mol |
| Topological Polar Surface Area | 1390 Ų |
| Heavy Atom Count | 233 |
| Formal Charge | 0 |
| Complexity | 7620 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 29 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.